TY  - JOUR
AU  - Martin, Miguel
AU  - Zielinski, Christoph
AU  - Ruiz-Borrego, Manuel
AU  - Carrasco, Eva
AU  - Ciruelos, Eva M
AU  - Muñoz, Montserrat
AU  - Bermejo, Begoña
AU  - Margeli, Mireia
AU  - Csöszi, Tibor
AU  - Anton, Antonio
AU  - Turner, Nicholas
AU  - Casas, Maria I
AU  - Morales, Serafin
AU  - Alba, Emilio
AU  - Calvo, Lourdes
AU  - de la Haba-Rodriguez, Juan
AU  - Ramos, Manuel
AU  - Murillo, Laura
AU  - Santaballa, Ana
AU  - Alonso-Romero, Jose L
AU  - Sanchez-Rovira, Pedro
AU  - Corsaro, Massimo
AU  - Huang, Xin
AU  - Thallinger, Christiane
AU  - Kahan, Zsuzsanna
AU  - Gil-Gil, Miguel
PY  - 2022
DO  - 10.1016/j.ejca.2022.03.006
UR  - http://hdl.handle.net/10668/22172
T2  - European journal of cancer (Oxford, England : 1990)
AB  - An earlier analysis of the PEARL phase III study showed that palbociclib plus endocrine therapy (ET) does not improve progression-free survival (PFS) over capecitabine in aromatase inhibitor-resistant, hormone receptor-positive/human epidermal growth...
LA  - en
PB  - Elsevier
KW  - CDK4/6 inhibitor
KW  - Capecitabine
KW  - Endocrine therapy
KW  - HER2–negative
KW  - Hormone receptor-positive metastatic breast cancer
KW  - Overall survival
KW  - Palbociclib
KW  - Antineoplastic combined chemotherapy protocols
KW  - Aromatase inhibitors
KW  - Breast neoplasms
KW  - Capecitabine
KW  - Female
KW  - Fulvestrant
KW  - Humans
KW  - Piperazines
KW  - Postmenopause
KW  - Pyridines
KW  - Receptor, ErbB-2
KW  - Receptors, estrogen
TI  - Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
TY  - research article
VL  - 168
ER  -